{"id":29108,"date":"2024-08-13T18:50:59","date_gmt":"2024-08-13T13:20:59","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=29108"},"modified":"2024-09-09T11:39:20","modified_gmt":"2024-09-09T06:09:20","slug":"pharma-news-for-ascendis-pharma-novartis-servier","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier","title":{"rendered":"FDA Approves Ascendis Pharma\u2019s YORVIPATH; ARS Pharma Gets FDA Green Light for First Nasal Spray; FDA Rejects Lykos\u2019 MDMA-Assisted PTSD Therapy; Novartis&#8217; FABHALTA Receives FDA Accelerated Approval; Servier Snags FDA Approval for Voranigo"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a06d1606e23e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a06d1606e23e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier\/#Ascendis_Pharma_Lands_Long-Awaited_FDA_Drug_Approval_in_Rare_Hormone_Deficiency\" >Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier\/#ARS_Pharma_Gets_FDA_Green_Light_for_First_Nasal_Spray_for_Severe_Allergic_Reactions\" >ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier\/#FDA_Rejects_Lykos_Mdma-Assisted_PTSD_Therapy_After_Negative_Adcomm\" >FDA Rejects Lykos\u2019 Mdma-Assisted PTSD Therapy After Negative Adcomm<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier\/#Novartis_IgAN_Ambition_Takes_Shape_With_Expanded_FDA_Nod_for_FABHALTA\" >Novartis&#8217; IgAN Ambition Takes Shape With Expanded FDA Nod for FABHALTA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier\/#Servier_Snags_FDA_Approval_For_Voranigo_The_First_Targeted_Therapy_for_a_Common_Type_of_Brain_Tumor\" >Servier Snags FDA Approval For Voranigo, The First Targeted Therapy for a Common Type of Brain Tumor<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-ascendis-pharma-lands-long-awaited-fda-drug-approval-in-rare-hormone-deficiency\"><span class=\"ez-toc-section\" id=\"Ascendis_Pharma_Lands_Long-Awaited_FDA_Drug_Approval_in_Rare_Hormone_Deficiency\"><\/span>Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Ascendis Pharma<\/strong> A\/S has announced that the <strong>FDA has approved<\/strong> <strong>YORVIPATH (palopegteriparatide; developed as TransCon PTH)<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypoparathyroidism-market\">hypoparathyroidism in adults.<\/a> YORVIPATH, a prodrug of parathyroid hormone (PTH[1-34]), is administered once daily and designed to provide continuous exposure to PTH over a 24-hour period. Hypoparathyroidism, affecting an estimated ~270K people in the 7MM, is a rare endocrine disease caused by insufficient levels of parathyroid hormone.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Jan Mikkelsen, Ascendis Pharma\u2019s President and CEO, expressed gratitude for the approval, stating, \u201cFDA approval of our second TransCon product, YORVIPATH, reflects our values and dedication to following the science to help patients, as well as our unwavering commitment these past years to addressing the significant unmet medical needs of the hypoparathyroidism community in the United States.\u201d Patty Keating, Executive Director of the HypoPARAthyroidism Association, added, \u201cWe are thankful that the seriousness of our condition has been understood and our voices heard. We look forward to having this new treatment option to help us move beyond the limits and risks of conventional therapy.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>The FDA&#8217;s approval was based on clinical data from the global Phase II PaTH Forward and Phase III PaTHway trials. Dr. Lynn Kohlmeier, an investigator in the PaTHway Trial, emphasized the importance of this approval, stating, \u201cThe ability to address the underlying cause of this disease is crucial and will be an important advancement for our patients with hypoparathyroidism.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Ascendis plans to launch YORVIPATH with a suite of patient services through its U.S. Ascendis Signature Access Program (A.S.A.P.), offering support and financial assistance. The company anticipates initial supply availability by the first quarter of 2025 and aims to commercialize existing manufactured product by the fourth quarter of 2024, pending FDA approval.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ars-pharma-gets-fda-green-light-for-first-nasal-spray-for-severe-allergic-reactions-nbsp\"><span class=\"ez-toc-section\" id=\"ARS_Pharma_Gets_FDA_Green_Light_for_First_Nasal_Spray_for_Severe_Allergic_Reactions\"><\/span>ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>ARS Pharmaceuticals, Inc.<\/strong> made an announcement that the <strong>FDA <\/strong>has <strong>approved neffy (epinephrine nasal spray)<\/strong> 2 mg for treating Type I Allergic Reactions, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/anaphylaxis-market\">anaphylaxis<\/a>, in adults and children weighing \u226530 kg (66 lbs). This approval marks the first significant innovation in epinephrine delivery in over 35 years and introduces the first needle-free option for managing severe allergic reactions.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Dr. Thomas B. Casale, from the University of South Florida, highlighted the importance of this development: \u201cUntil today, patients with severe allergic reactions only had one treatment option \u2013 an often painful and anxiety-inducing needle injection of epinephrine. FDA approval of neffy means that patients finally gain a long-awaited, needle-free, easy-to-carry epinephrine delivery method.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Type I allergic reactions can lead to life-threatening anaphylaxis, resulting in approximately 500,000 emergency room visits annually, with nearly 60% of patients not receiving epinephrine before arriving at the ER. Richard Lowenthal, CEO of ARS Pharmaceuticals, emphasized the impact of this new treatment: \u201cThis approval marks a watershed moment in addressing an unmet medical need for people with Type I allergies \u2013 a treatment alternative that avoids the need to inject epinephrine with a needle.\u201d<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>The FDA&#8217;s approval of neffy is based on data from five primary registration studies and several supportive studies. Dr. Jonathan Spergel from Children&#8217;s Hospital of Philadelphia noted, \u201cWe know that earlier administration is better, and for many, the needle is a barrier that causes dangerous hesitation. That is why the field has long pursued an effective treatment approach that does not require an injection.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-rejects-lykos-mdma-assisted-ptsd-therapy-after-negative-adcomm\"><span class=\"ez-toc-section\" id=\"FDA_Rejects_Lykos_Mdma-Assisted_PTSD_Therapy_After_Negative_Adcomm\"><\/span>FDA Rejects Lykos\u2019 Mdma-Assisted PTSD Therapy After Negative Adcomm<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA has declined to approve MDMA, commonly known as ecstasy, as a <a href=\"https:\/\/www.delveinsight.com\/report-store\/post-traumatic-stress-disorder-ptsd-market\">treatment for post-traumatic stress disorder (PTSD)<\/a>, Lykos Therapeutics announced on 9th Aug 2024. This decision is seen as a minor setback for the movement to use psychedelics in mental health treatments. The FDA&#8217;s decision followed an independent advisory committee&#8217;s recommendation against approval, citing insufficient evidence of the drug&#8217;s safety and effectiveness.<\/p>\n\n\n\n<p>The advisory committee raised concerns about poorly designed studies, allegations of sexual misconduct during clinical trials, and potential health risks, including heart problems and abuse. A review by FDA scientists also noted issues with trial execution, such as the likelihood that patients and therapists could guess who received the medication versus the placebo.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>Despite this rejection, experts remain optimistic about the future of psychedelic therapies. Holly Fernandez Lynch, an associate professor of medical ethics at the University of Pennsylvania, commented, \u201cI think it will be a temporary setback. The advisory committee and FDA gave very clear indications of what they\u2019re looking for in terms of study design and adverse event reporting.\u201d She believes that Lykos and other companies now have clearer guidelines to achieve future approvals.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>There are approximately four dozen MDMA trials in various stages of clinical development, indicating continued interest and research in this area. Advocates believe that, despite this setback, the path to FDA approval for psychedelic therapies remains promising.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novartis-igan-ambition-takes-shape-with-expanded-fda-nod-for-fabhalta\"><span class=\"ez-toc-section\" id=\"Novartis_IgAN_Ambition_Takes_Shape_With_Expanded_FDA_Nod_for_FABHALTA\"><\/span>Novartis&#8217; IgAN Ambition Takes Shape With Expanded FDA Nod for FABHALTA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Novartis announced that the FDA has granted accelerated approval for FABHALTA\u00ae (iptacopan), a first-in-class complement inhibitor, for reducing proteinuria in adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-market\">primary immunoglobulin A nephropathy (IgAN) <\/a>at risk of rapid disease progression. This approval is based on interim results from the Phase III APPLAUSE-IgAN study, which showed a significant 44% reduction in proteinuria at nine months compared to a 9% reduction in the placebo group.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe heterogeneous and progressive nature of IgA nephropathy has made it challenging to effectively treat this disease. Thankfully, the treatment landscape is rapidly evolving,\u201d said Professor Dana Rizk from the University of Alabama at Birmingham. \u201cI am thrilled that this advancement is now available to help enable a targeted treatment approach for IgAN patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>IgAN is a rare disease where the immune system attacks the kidneys, causing inflammation and proteinuria, and affects around 25 people per million globally each year. Despite standard care, up to 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years, often requiring dialysis or transplantation. FABHALTA&#8217;s favorable safety profile includes common adverse reactions such as upper respiratory tract infection, lipid disorder, and abdominal pain.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cToday\u2019s approval of FABHALTA as a first-in-class medicine for IgA nephropathy is an important milestone in our journey to evolve rare renal disease care,\u201d said Victor Bult\u00f3, President US, Novartis. The company is also developing two additional IgAN therapies: atrasentan and zigakibart, both in late-stage development. Bonnie Schneider, Director and Co-Founder of the IgAN Foundation, expressed hope, stating, \u201cToday\u2019s approval offers new hope for people living with IgA nephropathy as it represents a treatment innovation that provides us with a new way to fight this multifaceted disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-servier-snags-fda-approval-for-voranigo-the-first-targeted-therapy-for-a-common-type-of-brain-tumor\"><span class=\"ez-toc-section\" id=\"Servier_Snags_FDA_Approval_For_Voranigo_The_First_Targeted_Therapy_for_a_Common_Type_of_Brain_Tumor\"><\/span>Servier Snags FDA Approval For Voranigo, The First Targeted Therapy for a Common Type of Brain Tumor<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Servier announced that the FDA has approved VORANIGO\u00ae, an IDH1 and IDH2 inhibitor, for treating adults and pediatric patients aged 12 and older with <a href=\"https:\/\/www.delveinsight.com\/report-store\/astrocytoma-market\">Grade 2 astrocytoma<\/a> or <a href=\"https:\/\/www.delveinsight.com\/report-store\/oligodendroglioma-market\">oligodendroglioma <\/a>with susceptible IDH1 or IDH2 mutations following surgery. This approval marks a significant advancement in glioma treatment, providing patients with the convenience of a once-daily pill to manage their disease.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cToday\u2019s approval of VORANIGO is an enormous leap forward in cancer care, and a defining moment for people living with Grade 2 IDH-mutant glioma,\u201d said Arjun H. Prasad, Chief Commercial Officer, Servier Pharmaceuticals. \u201cVORANIGO offers patients unprecedented improvement in progression-free survival.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Gliomas, particularly those with IDH mutations, are common malignant brain tumors in adults under 50. VORANIGO works by inhibiting mutant IDH1 and IDH2 enzymes, helping control the disease. The Phase III INDIGO clinical trial demonstrated that VORANIGO significantly extended progression-free survival compared to placebo and was well-tolerated, with common adverse reactions including fatigue, COVID-19, musculoskeletal pain, diarrhea, and seizure.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA approval of VORANIGO marks a monumental breakthrough in glioma treatment, offering renewed hope for patients and their families,\u201d said Ralph DeVitto, President &amp; CEO of the American Brain Tumor Association. David K. Lee, CEO of Servier Pharmaceuticals, added, \u201cVORANIGO can offer patients and their families hope for the future.\u201d<\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency Ascendis Pharma A\/S has announced that the FDA has approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. YORVIPATH, a prodrug of parathyroid hormone (PTH[1-34]), is administered once daily and designed to provide continuous exposure to PTH over a [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":29110,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[7656,704,17786,22206,349,420,639,5789],"industry":[17225],"therapeutic_areas":[17240,17227,17228],"class_list":["post-29108","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-anaphylaxis","tag-fda","tag-hypoparathyroidism","tag-igan","tag-latest-pharma-news","tag-news","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Ascendis Pharma, Novartis, Servier<\/title>\n<meta name=\"description\" content=\"Ascendis Pharma&#039;s FDA Approval, ARS Pharma&#039;s Nasal Spray, FDA Rejects Lykos&#039; PTSD Therapy, Novartis&#039; Fabhalta accelerated, Servier&#039;s Voranigo\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Ascendis Pharma, Novartis, Servier\" \/>\n<meta property=\"og:description\" content=\"Ascendis Pharma&#039;s FDA Approval, ARS Pharma&#039;s Nasal Spray, FDA Rejects Lykos&#039; PTSD Therapy, Novartis&#039; Fabhalta accelerated, Servier&#039;s Voranigo\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-13T13:20:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-09T06:09:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/13184606\/pharma-news-for-ascendis-pharma-novartis-servier.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Ascendis Pharma, Novartis, Servier","description":"Ascendis Pharma's FDA Approval, ARS Pharma's Nasal Spray, FDA Rejects Lykos' PTSD Therapy, Novartis' Fabhalta accelerated, Servier's Voranigo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Ascendis Pharma, Novartis, Servier","og_description":"Ascendis Pharma's FDA Approval, ARS Pharma's Nasal Spray, FDA Rejects Lykos' PTSD Therapy, Novartis' Fabhalta accelerated, Servier's Voranigo","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-08-13T13:20:59+00:00","article_modified_time":"2024-09-09T06:09:20+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/13184606\/pharma-news-for-ascendis-pharma-novartis-servier.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier","name":"Pharma News | Ascendis Pharma, Novartis, Servier","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/13184606\/pharma-news-for-ascendis-pharma-novartis-servier.png","datePublished":"2024-08-13T13:20:59+00:00","dateModified":"2024-09-09T06:09:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Ascendis Pharma's FDA Approval, ARS Pharma's Nasal Spray, FDA Rejects Lykos' PTSD Therapy, Novartis' Fabhalta accelerated, Servier's Voranigo","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-ascendis-pharma-novartis-servier#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/13184606\/pharma-news-for-ascendis-pharma-novartis-servier.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/13184606\/pharma-news-for-ascendis-pharma-novartis-servier.png","width":772,"height":482,"caption":"pharma-news-for-ascendis pharma-novartis-servier"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/13184606\/pharma-news-for-ascendis-pharma-novartis-servier-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Anaphylaxis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hypoparathyroidism<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IgAN<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Anaphylaxis<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Hypoparathyroidism<\/span>","<span class=\"advgb-post-tax-term\">IgAN<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Aug 13, 2024","modified":"Updated on Sep 9, 2024"},"absolute_dates_time":{"created":"Posted on Aug 13, 2024 6:50 pm","modified":"Updated on Sep 9, 2024 11:39 am"},"featured_img_caption":"pharma-news-for-ascendis pharma-novartis-servier  \n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=29108"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29108\/revisions"}],"predecessor-version":[{"id":29115,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29108\/revisions\/29115"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/29110"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=29108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=29108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=29108"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=29108"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=29108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}